Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare neurological disease caused by the reactivation of latent John Cunningham polyomavirus. Hematological disorders associated with immunomodulatory monoclonal antibodies and hematopoietic stem cell transplantation (HSCT) are risk factors for PML. Blinatumomab is a novel antileukemic immunomodulatory agent and more effective for relapsed and refractory acute lymphoblastic leukemia (ALL) than conventional chemotherapy. But, blinatumomab suppresses humoral immunity due to long-lasting B-cell depletion during and after the treatment. The development of PML involves cellular immunity and impairment of humoral immunity. Although few cases of blinatumomab-related PML have been reported, the use of blinatumomab after allogeneic HSCT may increase the risk of developing PML. The current case report presents a patient of Philadelphia chromosome-positive ALL wherein PML developed after cord blood stem cell transplantation and administrating blinatumomab.
References
1.
Löffler
A
, Kufer
P
, Lutterbüse
R
, Zettl
F
, Daniel
PT
, Schwenkenbecher
JM
, A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
. Blood
. 2000 Mar 15
;95
(6
):2098
–103
. .2.
Kantarjian
H
, Stein
A
, Gökbuget
N
, Fielding
AK
, Schuh
AC
, Ribera
JM
, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
. N Engl J Med
. 2017 Mar 2
;376
(9
):836
–47
. .3.
Mori
Y
, Sasaki
K
, Ito
Y
, Kuriyama
T
, Ueno
T
, Kadowaki
M
, Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study
. Ann Hematol
. 2021 Jan
;100
(1
):197
–208
. .4.
Neil
EC
, DeAngelis
LM
. Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review
. Blood Adv
. 2017 Oct 18
;1
(23
):2041
–5
. .5.
Durali
D
, de Goër de Herve
MG
, Gasnault
J
, Taoufik
Y
. B cells and progressive multifocal leukoencephalopathy: search for the missing link
. Front Immunol
. 2015 May 19
;6
:241
. .6.
Sdrimas
K
, Diaz-Paez
M
, Camargo
JF
, Lekakis
LJ
. Progressive multifocal leukoencephalopathy after CAR T therapy
. Int J Hematol
. 2020 Jul
;112
(1
):118
–21
. .7.
Edahiro
T
, Kawase
T
, Nagoshi
H
, Fujino
K
, Toishigawa
K
, Miyama
T
, Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis
. Hematology
. 2021 Dec
;26
(1
):186
–98
. .8.
Berger
JR
, Aksamit
AJ
, Clifford
DB
, Davis
L
, Koralnik
IJ
, Sejvar
JJ
, PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section
. Neurology
. 2013 Apr 9
;80
(15
):1430
–8
. .9.
Amend
KL
, Turnbull
B
, Foskett
N
, Napalkov
P
, Kurth
T
, Seeger
J
. Incidence of progressive multifocal leukoencephalopathy in patients without HIV
. Neurology
. 2010 Oct 12
;75
(15
):1326
–32
. .10.
Schmidt-Hieber
M
, Schwender
J
, Heinz
WJ
, Zabelina
T
, Kühl
JS
, Mousset
S
, Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents
. Haematologica
. 2011 Jan
;96
(1
):142
–9
. .11.
Buckanovich
RJ
, Liu
G
, Stricker
C
, Luger
SM
, Stadtmauer
EA
, Schuster
SJ
, Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin’s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy
. Ann Hematol
. 2002 Jul
;81
(7
):410
–3
. .12.
Lee
HC
, Mulanovich
V
, Nieto
Y
. Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid Leukemia
. J Nati Compr Canc Net
. 2014
;12
:1660
–4
; quiz 1664. .13.
Zugmaier
G
, Gökbuget
N
, Klinger
M
, Viardot
A
, Stelljes
M
, Neumann
S
, Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
. Blood
. 2015 Dec 10
;126
(24
):2578
–84
. .14.
Zugmaier
G
, Topp
MS
, Alekar
S
, Viardot
A
, Horst
HA
, Neumann
S
, Long-term follow-up of serum immunoglobulin levels in Blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
. Blood Cancer J
. 2014 Sep 5
;4
(9
):244
. .15.
Maschmeyer
G
, De Greef
J
, Mellinghoff
SC
, Nosari
A
, Thiebaut-Bertrand
A
, Bergeron
A
, Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
. Leukemia
. 2019 Apr
;33
(4
):844
–62
. .16.
Stein
AS
, Larson
RA
, Schuh
AC
, Stevenson
W
, Lech-Maranda
E
, Tran
Q
, Exposure-adjusted adverse events comparing Blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
. Blood Adv
. 2018 Jul 10
;2
(13
):1522
–31
. .17.
Rambaldi
A
, Huguet
F
, Zak
P
, Cannell
P
, Tran
Q
, Franklin
J
, Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
. Blood Adv
. 2020 Apr 14
;4
(7
):1518
–25
. .18.
Avivi
I
, Wittmann
T
, Henig
I
, Kra-Oz
Z
, Szwarcwort Cohen
M
, Zuckerman
T
, Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation-can preemptive detection of John Cunningham virus be useful?
Int J Infect Dis
. 2014 Sep
;26
:107
–9
. .19.
Yoshida
H
, Ohshima
K
, Toda
J
, Kusakabe
S
, Masaie
H
, Yagi
T
, Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation
. Int J Hematol
. 2014 Jan
;99
(1
):95
–9
. .20.
Elphick
GF
, Querbes
W
, Jordan
JA
, Gee
GV
, Eash
S
, Manley
K
, The human polyomavirus, JCV, uses serotonin receptors to infect cells
. Science
. 2004 Nov 19
;306
(5700
):1380
–3
. .21.
Clifford
DB
, Nath
A
, Cinque
P
, Brew
BJ
, Zivadinov
R
, Gorelik
L
, A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
. J Neurovirol
. 2013 Aug
;19
(4
):351
–8
. .22.
Du Pasquier
RA
, Kuroda
MJ
, Zheng
Y
, Jean-Jacques
J
, Letvin
NL
, Koralnik
IJ
. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy
. Brain
. 2004 Sep
;127
(Pt 9
):1970
–8
. .23.
Balduzzi
A
, Lucchini
G
, Hirsch
HH
, Basso
S
, Cioni
M
, Rovelli
A
, Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient
. Bone Marrow Transplant
. 2011 Jul
;46
(7
):987
–92
. .24.
Tan
CS
, Bord
E
, Broge
TA
Jr, Glotzbecker
B
, Mills
H
, Gheuens
S
, Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy
. J Acquir Immune Defic Syndr
. 2012 Jul 1
;60
(3
):244
–8
. .25.
Walter
O
, Treiner
E
, Bonneville
F
, Mengelle
C
, Vergez
F
, Lerebours
F
, Treatment of progressive multifocal leukoencephalopathy with nivolumab
. N Engl J Med
. 2019 Apr 25
;380
(17
):1674
–6
. .26.
Cortese
I
, Muranski
P
, Enose-Akahata
Y
, Ha
SK
, Smith
B
, Monaco
M
, Pembrolizumab treatment for progressive multifocal leukoencephalopathy
. N Engl J Med
. 2019 Apr 25
;380
(17
):1597
–605
. .27.
Focosi
D
, Tuccori
M
, Maggi
F
. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab
. Rev Med Virol
. 2019 Nov
;29
(6
):e2077
. .28.
Steurer
M
, Clausen
J
, Gotwald
T
, Gunsilius
E
, Stockhammer
G
, Gastl
G
, Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab
. Transplantation
. 2003 Jul 27
;76
(2
):435
–6
. .29.
Gasnault
J
, de Goer de Herve
MG
, Mazet
AA
, Michot
JM
, Hendel-Chavez
H
, Seta
V
, Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy
. Open Forum Infect Dis
. 2014 Aug 26
;1
(2
):ofu074
. .30.
Wollebo
HS
, Bellizzi
A
, Kaminski
R
, Hu
W
, White
MK
, Khalili
K
. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection
. PLoS One
. 2015
;10
(9
):e0136046
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
